Medical School · Year 2 · Endocrine · includes a quiz and discussion video

Lecture 4: Thyroid Anatomy and Physiology

Unit 2.3: Endocrine System

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe the gross and microscopic anatomy of the thyroid gland
2. Explain thyroid hormone synthesis and regulation
3. Describe the transport and metabolism of thyroid hormones
4. Explain the cellular actions of thyroid hormones
5. Describe the physiologic effects of thyroid hormones on organ systems
6. Explain the hypothalamic-pituitary-thyroid axis and feedback

Lecture Outline

I. Thyroid Anatomy

The thyroid gland is the largest pure endocrine organ in the body, strategically positioned in the anterior neck where it can be palpated during physical examination—a remarkable feature for an endocrine gland. Understanding thyroid anatomy is essential for surgical approaches and for recognizing pathological enlargement (goiter).

Location and gross structure describe the thyroid as occupying the anterior neck at the level of the C5 to T1 vertebrae, wrapping around the anterolateral aspects of the trachea. The gland has a characteristic butterfly or H-shape, consisting of two lateral lobes (right and left) connected by a narrow isthmus that crosses the anterior trachea at approximately the second to fourth tracheal rings. Each lobe measures approximately 4 cm in height, 2 cm in width, and 2 cm in depth. The normal thyroid weighs 15-25 grams, though this varies with iodine intake and population. Approximately 50% of individuals have a pyramidal lobe, a superior midline extension representing a remnant of the thyroglossal duct; it extends from the isthmus toward the hyoid bone.

Anatomical relations of the thyroid have significant surgical implications. Anteriorly, the strap muscles (sternothyroid, sternohyoid, omohyoid) cover the gland. The trachea lies immediately posterior and medial, with the thyroid lobes wrapping around its anterolateral aspects—a large goiter can compress the trachea, causing stridor and dyspnea. The esophagus lies directly posterior, and goiters can cause dysphagia. The recurrent laryngeal nerves run in the tracheoesophageal groove, posterior to the thyroid lobes—these motor nerves to the intrinsic laryngeal muscles (except cricothyroid) are at risk during thyroidectomy, and injury causes hoarseness or, if bilateral, airway obstruction. The parathyroid glands, usually four in number, lie on the posterior surface of the thyroid—they must be identified and preserved during surgery to prevent hypocalcemia. The carotid sheath (containing the carotid artery, internal jugular vein, and vagus nerve) lies lateral.

Blood supply to the thyroid is abundant, reflecting its high metabolic activity. The superior thyroid artery, the first branch of the external carotid artery, descends to supply the upper pole. The inferior thyroid artery, arising from the thyrocervical trunk (a branch of the subclavian artery), ascends to supply the lower pole. In approximately 10% of individuals, a thyroid ima artery arises directly from the brachiocephalic trunk or aorta and ascends anterior to the trachea to supply the isthmus—it must be recognized to avoid bleeding during tracheostomy. Venous drainage occurs through the superior and middle thyroid veins (draining to the internal jugular vein) and the inferior thyroid veins (draining to the brachiocephalic veins).

<image>Panel A: Anterior view of thyroid showing butterfly-shaped gland with right and left lobes connected by isthmus across anterior trachea at C5-T1 level, pyramidal lobe extending superiorly toward hyoid bone. Panel B: Posterior view highlighting critical surgical structures including recurrent laryngeal nerves in tracheoesophageal groove bilaterally and four parathyroid glands on posterior surface. Panel C: Arterial blood supply showing superior thyroid artery from external carotid to upper pole, inferior thyroid artery from thyrocervical trunk to lower pole, and thyroid ima artery variant (10%). Panel D: Surrounding anatomical relations including strap muscles anteriorly, trachea and esophagus posteriorly, and carotid sheath laterally.</image>

II. Thyroid Histology

The microscopic anatomy of the thyroid is unique among endocrine glands, featuring a follicular architecture that stores large quantities of hormone precursor—enough to supply the body for several months even if synthesis completely ceased.

Follicular architecture constitutes the fundamental organizational unit of the thyroid. The gland consists of roughly spherical follicles, each approximately 50-500 μm in diameter, varying in size based on activity level. Each follicle is lined by a single layer of follicular epithelial cells (thyrocytes) surrounding a central lumen filled with colloid. This architecture creates an enormous storage capacity for thyroglobulin, the protein matrix containing thyroid hormone precursors. An inactive gland has large follicles with abundant colloid and flat epithelial cells; an active gland has smaller follicles with less colloid and taller, cuboidal to columnar epithelial cells actively processing thyroglobulin.

Follicular cells (thyrocytes) are the functional epithelial cells responsible for thyroid hormone synthesis. Their morphology reflects activity: cuboidal to low columnar in the active state, flattened (squamous) in the quiescent state. The apical surface faces the colloid and bears microvilli that increase surface area for secretion and endocytosis. The basolateral surface faces the rich capillary network and contains the sodium-iodide symporter (NIS) for iodide uptake. Follicular cells synthesize thyroglobulin, secrete it into the colloid, iodinate it, couple iodinated tyrosines, and ultimately retrieve and process it to release T3 and T4.

Parafollicular cells (C cells) are the second cell type within the thyroid, scattered between follicles or within the follicular basement membrane. They derive from the neural crest (migrating into the thyroid from the ultimobranchial body during development), in contrast to follicular cells which derive from endoderm. C cells produce calcitonin, a peptide hormone that lowers serum calcium by inhibiting osteoclast activity and increasing renal calcium excretion. Physiologically, calcitonin's role in calcium homeostasis is minor in humans (PTH and vitamin D are far more important), and even total thyroidectomy does not cause hypercalcemia. Clinically, C cells are significant because medullary thyroid carcinoma arises from them, and calcitonin serves as a tumor marker.

Colloid is the proteinaceous material filling the follicular lumen. It consists primarily of thyroglobulin (Tg), a 660-kDa glycoprotein synthesized by follicular cells and secreted into the lumen. Thyroglobulin contains approximately 70 tyrosine residues, which serve as substrates for iodination and hormone synthesis. The colloid appears eosinophilic (pink) on H&E staining. Colloid volume varies inversely with gland activity: quiescent glands accumulate abundant colloid; active glands deplete it through endocytosis.

<image>Panel A: Low-power thyroid histology showing multiple follicles of varying sizes with colloid-filled lumens (pink/eosinophilic) surrounded by single layer of follicular epithelial cells. Panel B: Comparison of active follicle (smaller, less colloid, taller cuboidal cells with microvilli) versus quiescent follicle (larger, abundant colloid, flattened epithelium). Panel C: Follicular cell ultrastructure showing apical surface with microvilli facing colloid, basolateral NIS transporter facing capillary, with functions including Tg synthesis, iodination, and T3/T4 release. Panel D: Parafollicular C cells between follicles showing neural crest origin, calcitonin secretion, and clinical significance as origin of medullary thyroid carcinoma with calcitonin as tumor marker.</image>

III. Thyroid Hormone Synthesis

Thyroid hormone synthesis is a complex, multi-step process occurring at the interface between follicular cells and colloid. The process requires adequate iodine supply, functional enzymes, and intact regulatory mechanisms.

Iodide transport begins at the basolateral membrane of follicular cells. The sodium-iodide symporter (NIS), encoded by the SLC5A5 gene, actively transports iodide (I⁻) from the bloodstream into follicular cells against a concentration gradient, using the energy of the sodium gradient established by Na⁺/K⁺-ATPase. This process concentrates iodide to 20-40 times plasma levels within the gland. NIS expression is stimulated by TSH. At the apical membrane, pendrin (SLC26A4) facilitates iodide transport into the colloid. Competitive inhibitors of NIS include perchlorate (ClO₄⁻), thiocyanate (SCN⁻), and pertechnetate (TcO₄⁻)—these can be used diagnostically (pertechnetate scanning) or therapeutically (perchlorate to reduce iodine uptake).

Thyroid peroxidase (TPO), the key enzyme of hormone synthesis, is located on the apical membrane of follicular cells with its catalytic domain extending into the colloid. TPO requires hydrogen peroxide (H₂O₂) as a co-substrate, generated by the dual oxidase enzymes DUOX1 and DUOX2. TPO catalyzes three critical reactions: oxidation of iodide (I⁻) to reactive iodine (I•), organification (also called iodination)—the incorporation of iodine onto tyrosine residues of thyroglobulin to form monoiodotyrosine (MIT) and diiodotyrosine (DIT), and coupling of iodinated tyrosines within the thyroglobulin molecule.

The coupling reaction determines which thyroid hormone is formed. The coupling of two DIT residues produces T4 (thyroxine), the predominant thyroid hormone synthesized (about 90%). The coupling of one DIT with one MIT produces T3 (triiodothyronine), the more biologically active hormone (about 10%). Coupling of two MIT residues would produce biologically inactive diiodothyronine. The ratio of T4 to T3 production is approximately 10-20:1, meaning most circulating T3 is derived from peripheral conversion of T4 rather than direct thyroidal secretion.

Antithyroid drugs target these synthetic steps. Propylthiouracil (PTU) and methimazole are thionamides that inhibit TPO, blocking both organification and coupling. PTU additionally inhibits peripheral T4 to T3 conversion by type 1 deiodinase, making it useful in thyroid storm. High-dose iodide (Wolff-Chaikoff effect) transiently inhibits organification—this is exploited therapeutically with potassium iodide preparations (Lugol's solution, SSKI) to acutely reduce thyroid hormone synthesis before surgery or in thyroid storm.

<image>Panel A: Iodide transport showing sodium-iodide symporter (NIS) on basolateral membrane concentrating iodide 20-40x using Na+ gradient, pendrin on apical membrane transporting iodide to colloid, and perchlorate/thiocyanate as competitive NIS inhibitors. Panel B: TPO-catalyzed reactions at apical membrane including oxidation (I- to reactive iodine using H2O2 from DUOX2), organification forming MIT and DIT, and coupling reactions. Panel C: Hormone production showing DIT + DIT coupling to form T4 (90% of production) and DIT + MIT coupling to form T3 (10% of production) within thyroglobulin backbone. Panel D: Antithyroid drug targets showing PTU and methimazole blocking TPO, high-dose iodide causing Wolff-Chaikoff effect, and PTU additionally blocking peripheral T4-to-T3 conversion.</image>

IV. Thyroid Hormone Secretion

The release of thyroid hormones from the gland involves retrieval of thyroglobulin from the colloid, proteolytic processing, and secretion of free hormones into the circulation. This process is tightly regulated by TSH.

Secretion process occurs through several steps. TSH binds its receptor on the basolateral membrane of follicular cells. The TSH receptor is a G protein-coupled receptor that signals primarily through Gs-cAMP-PKA, stimulating all aspects of thyroid function: iodide uptake, thyroglobulin synthesis, hormone synthesis, and hormone secretion. TSH also stimulates follicular cell growth and proliferation. Follicular cells extend pseudopods that engulf colloid at the apical surface through pinocytosis or endocytosis, internalizing thyroglobulin. The endocytic vesicles fuse with lysosomes, and lysosomal proteases digest thyroglobulin, releasing T4, T3, MIT, and DIT. T4 and T3 are transported across the basolateral membrane and released into the bloodstream. MIT and DIT are deiodinated by intracellular deiodinases, and the liberated iodide is recycled for new hormone synthesis—this is an important iodine conservation mechanism.

Thyroid hormone output under normal conditions is approximately 80-100 μg of T4 per day and only 6-8 μg of T3 per day from the thyroid directly. The majority of circulating T3 (approximately 80%) is derived from peripheral conversion of T4 by deiodinase enzymes, primarily in the liver and kidney. The thyroid gland stores a remarkable quantity of hormone precursor—enough to maintain normal serum hormone levels for 2-3 months even if synthesis completely ceased.

TSH receptor characteristics are clinically important. The receptor contains an extracellular domain where TSH binds and where autoantibodies can also interact. Thyroid-stimulating immunoglobulins (TSI), the pathogenic antibodies in Graves' disease, bind the extracellular domain and mimic TSH action, causing continuous stimulation (hyperthyroidism). TSH receptor blocking antibodies can also occur, inhibiting TSH action and causing hypothyroidism (atrophic thyroiditis). Rarely, activating mutations in the TSH receptor cause autonomous hyperthyroidism (toxic adenoma, familial non-autoimmune hyperthyroidism).

<image>Panel A: TSH signaling showing TSH binding to basolateral receptor, Gs-cAMP-PKA cascade activation, with downstream effects including increased NIS expression, Tg synthesis, TPO activity, endocytosis, and cell growth. Panel B: Secretion process showing pseudopod extension engulfing colloid, endocytic vesicle formation, lysosomal fusion with proteolytic digestion, and release of T4, T3, MIT, and DIT. Panel C: Thyroid hormone output showing T4 80-100 mcg/day and T3 6-8 mcg/day directly from thyroid, with 80% of circulating T3 from peripheral conversion, plus MIT/DIT deiodination for iodide recycling. Panel D: TSH receptor clinical significance showing normal TSH binding versus stimulating antibodies (Graves disease causing hyperthyroidism) versus blocking antibodies (atrophic thyroiditis causing hypothyroidism).</image>

V. Thyroid Hormone Transport

Once secreted, thyroid hormones circulate primarily bound to plasma proteins, with only a tiny free fraction available to enter cells and exert biological effects. Understanding transport is essential for interpreting thyroid function tests.

Plasma binding proteins carry over 99% of circulating thyroid hormones. Thyroxine-binding globulin (TBG) has the highest affinity and carries approximately 70% of circulating T4 and T3. It is synthesized by the liver, and its serum concentration is affected by various conditions. Transthyretin (TTR), formerly called prealbumin, has intermediate affinity and carries approximately 15% of thyroid hormones. Albumin has low affinity but high capacity due to its abundance, carrying approximately 15%. The unbound or free hormone fraction is tiny: approximately 0.02% of total T4 and 0.3% of total T3 are free. This free fraction is the biologically active portion that enters cells and exerts effects.

Factors affecting TBG alter total hormone levels but not free hormone levels (in the steady state). Increased TBG occurs with estrogen (pregnancy, oral contraceptive pills, estrogen therapy), hepatitis, and rare genetic TBG excess. When TBG increases, more hormone becomes bound, initially lowering free hormone. This triggers TSH release, which stimulates more hormone production until free hormone normalizes—but now total hormone is elevated. Decreased TBG occurs with androgens, glucocorticoids, liver disease (decreased synthesis), nephrotic syndrome (urinary loss), and genetic TBG deficiency. The opposite sequence occurs: less binding, transiently elevated free hormone, feedback suppression, reduced production, lower total but normal free hormone. These changes explain why total T4 or T3 can be misleading—free hormone measurements better reflect thyroid status.

The free hormone concept is fundamental: only free hormone enters cells, so only free hormone is biologically active. Changes in binding protein levels alter total hormone without changing free hormone (after equilibration). However, in acute or non-steady-state situations, free hormone may be transiently altered before equilibration occurs. Some conditions (severe illness, certain drugs) alter binding characteristics or displace hormone from proteins, affecting the total/free relationship.

<image>Panel A: Binding protein distribution showing TBG 70% (high affinity), transthyretin 15% (intermediate affinity), and albumin 15% (low affinity, high capacity), with free hormone fraction of 0.02% T4 and 0.3% T3 as biologically active. Panel B: Dynamic equilibrium between bound and free hormone, with only free hormone entering target cells for biological effect. Panel C: Factors affecting TBG showing increased TBG (estrogen, pregnancy, OCP, hepatitis) causing elevated total but normal free T4, versus decreased TBG (androgens, glucocorticoids, liver disease, nephrotic syndrome) causing decreased total but normal free T4. Panel D: Clinical comparison showing why free hormone better reflects thyroid status using patient on estrogen (high total T4 with normal free T4, euthyroid) versus hyperthyroid patient (both high total and high free T4).</image>

VI. Thyroid Hormone Metabolism

The metabolism of thyroid hormones, particularly the conversion of T4 to T3 by deiodinase enzymes, determines the bioavailability of active hormone and provides an additional layer of regulation beyond thyroidal secretion.

Peripheral conversion is critical because T4 is essentially a prohormone while T3 is the active hormone (T3 binds thyroid hormone receptors with 10-15 times greater affinity than T4). Although the thyroid produces both, approximately 80% of circulating T3 comes from peripheral deiodination of T4 in tissues, particularly liver and kidney. This peripheral conversion allows tissue-specific regulation of thyroid hormone action.

Deiodinase enzymes catalyze removal of iodine from thyroid hormones. Type 1 deiodinase (D1), found primarily in liver, kidney, and thyroid, converts T4 to T3 by removing iodine from the outer ring—it is responsible for most circulating T3 production. D1 can also convert T4 to reverse T3 (rT3) through inner ring deiodination. D1 is inhibited by propylthiouracil. Type 2 deiodinase (D2), found in brain, pituitary, and brown adipose tissue, converts T4 to T3 locally within these tissues. D2 in the pituitary is particularly important for feedback: it converts T4 to T3 within pituitary thyrotrophs, and this locally generated T3 mediates negative feedback on TSH secretion. Type 3 deiodinase (D3) is the inactivating enzyme, converting T4 to rT3 and T3 to T2 (inactive metabolites). D3 protects tissues from excess thyroid hormone and is highly expressed in the placenta, protecting the fetus from maternal thyroid hormone.

T3 versus reverse T3 (rT3) represents alternative metabolic pathways. T3 is biologically active, formed by outer ring deiodination of T4. Reverse T3 is biologically inactive, formed by inner ring deiodination of T4. The balance between T3 and rT3 production is regulated by physiological conditions. In euthyroid sick syndrome (also called non-thyroidal illness syndrome), which occurs during severe illness, fasting, or major physiological stress, D1 activity decreases and D3 activity increases, shifting metabolism toward rT3 and away from T3. This results in low T3, elevated rT3, and often normal or low T4 and TSH—a pattern that should not be mistaken for hypothyroidism and does not require treatment.

Factors affecting T4 to T3 conversion include illness (major illness decreases conversion, causing low T3 syndrome), fasting and malnutrition, certain medications (amiodarone inhibits D1; propylthiouracil inhibits D1; glucocorticoids inhibit D1; propranolol inhibits D1), and selenium deficiency (deiodinases are selenoproteins).

<image>Panel A: Deiodinase reactions showing T4 with two pathways: outer ring deiodination by D1/D2 producing active T3, and inner ring deiodination by D3 producing inactive rT3, with T3 further inactivated to T2. Panel B: Deiodinase enzyme tissue distribution showing D1 (liver, kidney, thyroid producing most circulating T3, inhibited by PTU), D2 (brain, pituitary, brown adipose for local T3 and TSH feedback), and D3 (placenta, CNS as inactivating enzyme). Panel C: Euthyroid sick syndrome showing metabolic shift in illness with decreased D1 and increased D3 activity causing low T3 and elevated rT3, emphasizing this is not hypothyroidism and does not require treatment. Panel D: Factors affecting T4-to-T3 conversion including illness, fasting, amiodarone, PTU, propranolol, glucocorticoids, and selenium deficiency.</image>

VII. Cellular Actions of Thyroid Hormones

Thyroid hormones exert their effects primarily through nuclear receptors that regulate gene transcription, though rapid non-genomic effects also occur. Understanding these mechanisms explains the diverse physiological effects of thyroid hormones.

Nuclear receptors mediate most thyroid hormone actions. Thyroid hormone receptors (TRs) belong to the nuclear receptor superfamily, functioning as ligand-activated transcription factors. Two genes encode thyroid receptors: TRα (chromosome 17) is predominantly expressed in heart, bone, brain, and skeletal muscle; TRβ (chromosome 3) is predominantly expressed in liver, pituitary, and brain. Each gene produces multiple isoforms through alternative splicing. TRβ2 in the pituitary is particularly important for negative feedback—mutations causing resistance to thyroid hormone at TRβ impair feedback, resulting in elevated TSH and thyroid hormones. T3 binds TRs with approximately 10-fold higher affinity than T4, explaining why T3 is the active hormone.

Mechanism of action involves transcriptional regulation. T3 enters cells via specific membrane transporters, with monocarboxylate transporter 8 (MCT8) being particularly important for brain uptake—mutations in MCT8 cause severe neurological impairment (Allan-Herndon-Dudley syndrome) despite normal serum thyroid hormones. In the nucleus, TRs form heterodimers with retinoid X receptors (RXR) and bind to thyroid hormone response elements (TREs) in the promoter regions of target genes. In the absence of T3, the TR-RXR complex recruits corepressors that silence gene transcription. When T3 binds, corepressors are released and coactivators are recruited, activating transcription. Target genes include those encoding Na⁺/K⁺-ATPase (increasing metabolic rate), uncoupling proteins (thermogenesis), β-adrenergic receptors (cardiovascular effects), myosin heavy chain (cardiac contractility), and many metabolic enzymes.

Non-genomic effects occur rapidly (within minutes) and do not require gene transcription. These include effects on ion channels, mitochondrial function, and signaling pathways. A cell surface receptor, integrin αVβ3, binds T4 and T3, activating MAPK signaling pathways that affect angiogenesis and cell proliferation. Mitochondrial effects include increased oxidative phosphorylation and thermogenesis. The clinical significance of non-genomic effects is still being elucidated.

<image>Panel A: Cellular uptake showing T3 and T4 crossing cell membrane via MCT8 transporter (mutations causing Allan-Herndon-Dudley syndrome), with intracellular T4-to-T3 conversion by D2 and T3 entering nucleus. Panel B: Nuclear receptor mechanism showing TR-RXR heterodimer on thyroid hormone response elements, comparing silenced state (corepressors bound without T3) versus activated state (coactivators recruited with T3 binding). Panel C: TR isoform tissue distribution showing TRα (heart, bone, skeletal muscle, brain) and TRβ (liver, pituitary), with TRβ mutations causing thyroid hormone resistance syndrome. Panel D: Genomic targets (Na+/K+-ATPase for metabolic rate, uncoupling proteins for thermogenesis, beta-adrenergic receptors, myosin heavy chain) and non-genomic effects via integrin αVβ3 receptor and mitochondrial pathways.</image>

VIII. Physiologic Effects of Thyroid Hormones

Thyroid hormones affect virtually every organ system, increasing basal metabolic rate, supporting normal growth and development, and modulating cardiovascular, neurological, and metabolic function.

Metabolic effects are the most characteristic actions of thyroid hormones. The basal metabolic rate (BMR) increases as thyroid hormones stimulate oxygen consumption and heat production in virtually all tissues. This calorigenic effect results from increased Na⁺/K⁺-ATPase activity (which consumes significant ATP), increased mitochondrial oxidative phosphorylation, and uncoupling of oxidative phosphorylation via uncoupling proteins, generating heat rather than ATP (thermogenesis). In hyperthyroidism, patients experience heat intolerance, sweating, weight loss despite increased appetite, and elevated body temperature. In hypothyroidism, patients experience cold intolerance, weight gain despite decreased appetite, and low body temperature.

Carbohydrate metabolism is enhanced in multiple ways: increased intestinal glucose absorption, increased gluconeogenesis and glycogenolysis, and increased tissue glucose utilization. The net effect in hyperthyroidism is often mild hyperglycemia and worsened glucose control in diabetics. Lipid metabolism shows increased lipolysis and increased LDL receptor expression. The LDL receptor effect is clinically important: hypothyroidism causes hypercholesterolemia (reduced LDL clearance), while hyperthyroidism lowers cholesterol. Unexplained hypercholesterolemia should prompt TSH measurement. Protein metabolism shows increased both synthesis and degradation; in hyperthyroidism, degradation exceeds synthesis, causing muscle wasting and weakness.

Cardiovascular effects are prominent and clinically important. Thyroid hormones increase chronotropy (heart rate) primarily by upregulating β-adrenergic receptors and by direct effects on pacemaker cells. They increase inotropy (contractility) through increased myosin heavy chain α expression (the faster isoform). They decrease systemic vascular resistance through direct vascular relaxation and increased metabolic demand. The combination of increased contractility and decreased afterload increases cardiac output substantially. Hyperthyroidism causes a high-output state with tachycardia, increased pulse pressure, palpitations, and can precipitate atrial fibrillation and heart failure. Hypothyroidism causes bradycardia, decreased cardiac output, pericardial effusion, and diastolic hypertension (from increased vascular resistance).

Nervous system effects are critical, especially during development. Thyroid hormones are essential for normal brain development—cretinism (severe congenital hypothyroidism) causes intellectual disability, spasticity, deaf-mutism, and short stature if untreated. In adults, hyperthyroidism causes tremor, anxiety, hyperreflexia, and insomnia; hypothyroidism causes cognitive slowing, depression, delayed reflexes (classically delayed relaxation phase of ankle jerk), and lethargy.

<image>Panel A: Metabolic effects showing increased BMR, thermogenesis via uncoupling proteins, and Na+/K+-ATPase activity, comparing hyperthyroid (heat intolerance, weight loss, sweating) versus hypothyroid (cold intolerance, weight gain). Panel B: Cardiovascular effects showing increased heart rate (beta-receptor upregulation), contractility (myosin switch), and decreased SVR, comparing hyperthyroid (tachycardia, high output, AF risk) versus hypothyroid (bradycardia, low output, pericardial effusion). Panel C: Lipid metabolism showing increased LDL receptor expression improving cholesterol clearance, with hypothyroid hypercholesterolemia highlighted as indication to check TSH. Panel D: Nervous system effects showing critical role in brain development (cretinism from congenital hypothyroidism), comparing adult hyperthyroid (tremor, anxiety, hyperreflexia) versus hypothyroid (cognitive slowing, depression, delayed reflex relaxation).</image>

IX. Hypothalamic-Pituitary-Thyroid Axis

The hypothalamic-pituitary-thyroid (HPT) axis is a classic example of hormonal feedback regulation, maintaining thyroid hormone levels within a narrow physiological range through negative feedback loops.

Regulatory hierarchy involves three levels. The hypothalamus produces thyrotropin-releasing hormone (TRH), a tripeptide (pyroglutamyl-histidyl-proline-amide) synthesized in the paraventricular nucleus and released into the hypophyseal portal system. The anterior pituitary contains thyrotrophs that express TRH receptors (GPCRs) and respond by synthesizing and releasing thyroid-stimulating hormone (TSH). TSH is a glycoprotein hormone with an α subunit (shared with FSH, LH, and hCG) and a unique β subunit conferring specificity. The thyroid gland expresses TSH receptors on follicular cells and responds by increasing all aspects of thyroid hormone synthesis and secretion, producing T4 and T3.

Negative feedback maintains homeostasis. T3 is the primary feedback signal at both hypothalamic and pituitary levels. At the pituitary, T3 inhibits TSH synthesis and release by suppressing the TSH β subunit gene and reducing thyrotroph responsiveness to TRH. Type 2 deiodinase (D2) in the pituitary converts T4 to T3 locally, meaning that circulating T4 levels strongly influence pituitary T3 and thus feedback. At the hypothalamus, T3 inhibits TRH gene expression. This negative feedback explains why serum TSH changes inversely with thyroid hormone levels: when T4/T3 fall, TSH rises; when T4/T3 rise, TSH falls.

The log-linear relationship between TSH and free T4 is clinically important. Small changes in free T4 produce large, logarithmic changes in TSH. This means TSH is the most sensitive indicator of thyroid status—TSH becomes abnormal before free T4 leaves the normal range in early thyroid dysfunction. This sensitivity makes TSH the ideal first-line screening test for thyroid disease. However, the relationship fails in pituitary disease (secondary hypothyroidism), where TSH cannot appropriately respond to low T4.

TSH regulation involves additional factors beyond T3 feedback. TRH stimulates TSH release (acts as the setpoint). Somatostatin inhibits TSH release (providing additional negative modulation). Dopamine inhibits TSH release, explaining why dopamine agonists can suppress TSH. Glucocorticoids suppress TSH, relevant in critical illness. TSH secretion follows a circadian rhythm with a nocturnal peak, and secretion is pulsatile.

<image>Panel A: Three-level HPT axis hierarchy showing hypothalamus (PVN producing TRH), anterior pituitary (thyrotrophs producing TSH), and thyroid (follicular cells producing T4 and T3), with stimulatory signals descending and T3 feedback inhibiting both TSH and TRH. Panel B: Negative feedback mechanism showing TSH rises when T4/T3 fall (primary hypothyroidism) and TSH falls when T4/T3 rise (hyperthyroidism), with pituitary D2 converting T4 to T3 for feedback regulation. Panel C: Log-linear TSH-T4 relationship demonstrating that small T4 changes cause large TSH changes, making TSH the most sensitive first-line screening test for thyroid dysfunction. Panel D: Additional TSH regulators including TRH (stimulates/setpoint), somatostatin (inhibits), dopamine (inhibits), and glucocorticoids (suppress), with exception noted for secondary hypothyroidism where TSH is inappropriately low.</image>

X. Thyroid Function Tests

Thyroid function testing forms the cornerstone of thyroid disease diagnosis. Understanding the appropriate use and interpretation of these tests is essential for accurate diagnosis.

TSH is the most sensitive and important thyroid function test. As the first-line screening test for thyroid dysfunction, TSH should be measured in any patient with suspected thyroid disease. Normal range is approximately 0.4-4.0 mIU/L (though upper limit varies by age, with higher values acceptable in the elderly). Elevated TSH indicates primary hypothyroidism: the thyroid is underproducing, so the pituitary compensates by increasing TSH. Suppressed TSH indicates hyperthyroidism (or, less commonly, central hypothyroidism): excess thyroid hormone suppresses pituitary TSH, or pituitary disease prevents appropriate TSH production. TSH alone can establish the diagnosis in most cases; free T4 confirms and quantifies the abnormality.

Free T4 (FT4) measures the unbound, biologically active fraction of thyroxine. It is the preferred measurement over total T4 because it is not affected by binding protein changes. Free T4 is used to confirm and characterize thyroid dysfunction detected by TSH abnormalities and to monitor thyroid hormone replacement. In secondary (central) hypothyroidism, where TSH cannot be used, free T4 is the primary monitoring parameter.

T3 measurements (total or free) are useful in specific situations. In hyperthyroidism, some patients have T3 toxicosis—elevated T3 with normal T4, often seen in early Graves' disease or toxic nodules. T3 measurement helps confirm hyperthyroidism and assess severity. In hypothyroidism, T3 is less useful because it may remain normal due to compensatory increased conversion.

Interpretation patterns correlate TSH and free T4 findings with specific diagnoses. Elevated TSH with low free T4 indicates primary hypothyroidism. Elevated TSH with normal free T4 indicates subclinical hypothyroidism (the TSH is elevated compensating for a subtle decrease in thyroid function). Low TSH with high free T4 indicates hyperthyroidism (primary, whether Graves' or toxic nodule). Low TSH with normal free T4 (and T3) indicates subclinical hyperthyroidism or T3 toxicosis (check T3). Low TSH with low free T4 suggests central (secondary) hypothyroidism—the pituitary is failing to produce TSH appropriately. Elevated TSH with elevated free T4 is the paradoxical pattern suggesting either TSH-secreting adenoma (thyrotropinoma) or thyroid hormone resistance syndrome.

Thyroid antibodies help identify the etiology of thyroid dysfunction. Anti-thyroid peroxidase (anti-TPO) antibodies are elevated in Hashimoto's thyroiditis and are the most sensitive marker for autoimmune thyroid disease. Anti-thyroglobulin (anti-Tg) antibodies are also elevated in Hashimoto's and can interfere with thyroglobulin measurement in thyroid cancer monitoring. TSH receptor antibodies (TRAb/TSI) are pathognomonic for Graves' disease.

<image>Panel A: TSH as first-line screening test (reference range 0.4-4.0 mIU/L) with high TSH prompting Free T4 to confirm hypothyroidism and low TSH prompting Free T4 and T3 to characterize hyperthyroidism. Panel B: Interpretation grid showing TSH/Free T4 combinations with diagnoses: primary hypothyroidism (high TSH, low FT4), subclinical hypothyroidism (high TSH, normal FT4), hyperthyroidism (low TSH, high FT4), subclinical hyperthyroidism (low TSH, normal FT4), central hypothyroidism (low TSH, low FT4), and TSHoma/resistance (high TSH, high FT4). Panel C: Special patterns including T3 toxicosis (low TSH, normal FT4, high T3) and guidance to check Free T4 in suspected pituitary disease where TSH cannot guide management. Panel D: Thyroid antibody testing showing anti-TPO (most sensitive Hashimoto marker), anti-Tg (Hashimoto, interferes with Tg monitoring), and TRAb/TSI (pathognomonic for Graves disease).</image>

Summary

The thyroid gland's butterfly shape wraps around the anterior trachea at C5-T1, with critical surgical relations including the recurrent laryngeal nerves (posterior) and parathyroid glands. Histologically, thyroid follicles contain colloid (thyroglobulin storage) lined by follicular cells; parafollicular C cells produce calcitonin.

Thyroid hormone synthesis requires iodide uptake (NIS), oxidation and organification by TPO (inhibited by thionamides), and coupling within thyroglobulin. TSH stimulates all aspects of synthesis and secretion via its receptor, a target of stimulating antibodies in Graves' disease.

Thyroid hormones circulate 99%+ protein-bound; only free hormone (0.02% T4, 0.3% T3) is active. T4 is a prohormone converted to active T3 by deiodinases (D1, D2) or to inactive rT3 (D3). In illness, conversion shifts toward rT3 (euthyroid sick syndrome).

Thyroid hormones act through nuclear receptors (TR) that regulate gene transcription, increasing metabolic rate, cardiac output, and nervous system activity. Development requires adequate thyroid hormone—congenital deficiency causes cretinism.

The HPT axis maintains homeostasis through TRH→TSH→T4/T3 with T3 feedback inhibition. The log-linear TSH-T4 relationship makes TSH the most sensitive indicator of thyroid status. Interpretation: elevated TSH = hypothyroidism; suppressed TSH = hyperthyroidism (except central disease).

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown